Where to buy ALD-52 for sale online

When it comes to purchasing research chemicals like ALD-52, finding a reliable seller is of paramount importance. The online market for designer drugs and research chemicals has grown substantially in recent years, but with this growth comes both reputable and questionable vendors. It’s crucial to exercise caution and conduct thorough research before making a purchase.
One of the primary concerns when searching for ALD-52 online is the vendor’s credibility. Not all sellers are created equal, and some may offer products of questionable quality or authenticity. It’s essential to seek out vendors with a solid reputation within the research chemical community. Reading reviews, checking for customer feedback, and verifying the vendor’s credentials can help ensure a more secure transaction.
Moreover, the legality of ALD-52 varies from one country to another and even within regions of the same country. A reputable seller should provide clear information regarding the legality of ALD-52 in your area and not offer it for sale if it’s illegal in your jurisdiction.
Price is another factor to consider when evaluating sellers. While lower prices may be tempting, they could indicate subpar product quality or even a scam. A trustworthy vendor typically offers competitive pricing within the research chemical market, but prices that seem too good to be true should raise red flags.
Additionally, customer support and communication are critical to evaluating research chemical vendors. Reliable sellers are responsive to inquiries and provide detailed information about their products, including purity, lab testing, and handling instructions. Steer clear of vendors who are evasive or unresponsive to your questions.


1-Acetyl-N,N-diethyllysergamide, commonly known as ALD-52 or 1-Acetyl-LSD, belongs to the lysergamide class of lesser-known psychedelic compounds. When ingested, it induces psychedelic effects similar to LSD, sharing structural similarities with other lysergamides like LSD and 1P-LSD, resulting in mostly indistinguishable effects.
Discovered initially during Albert Hofmann’s exploration of LSD analogs, ALD-52 remained relatively obscure until the 1960s, when it entered Western youth counterculture. It became widely recognized under the famous “Orange Sunshine” moniker, although this association was later debunked (see the section below).
In his commentary within the book “TiHKAL” (Tryptamines I Have Known and Loved), Alexander Shulgin briefly discusses ALD-52. Shulgin’s insights rely on second-hand accounts, suggesting that doses ranging from 50 to 175 µg produce effects not markedly different from LSD. According to his reports, ALD-52 generates fewer visual distortions, less anxiety, and reduced tenseness than LSD while being somewhat less potent. Another source even attests to the two substances being virtually indistinguishable.
Like LSD, ALD-52 does not meet the scientific community’s criteria for addiction or toxicity. Nevertheless, unforeseeable adverse reactions such as anxiety, paranoia, delusions, and psychosis remain possible, especially among individuals predisposed to psychiatric conditions. While negative experiences, often referred to as “bad trips,” can often be attributed to factors like user inexperience or inadequate preparation of set and setting, they can occur spontaneously, even in seasoned users. Therefore, if chosen for use, it is strongly recommended to approach this potent, enduring hallucinogen with thorough preparation and a commitment to harm reduction practices.

IUPAC name
CAS Number3270-02-8 
PubChem CID201111
CompTox Dashboard (EPA)DTXSID20186370
Chemical and physical data
Molar mass365.477 g·mol−1

History and culture

In 1968 and 1969, an infamous batch of LSD, famously referred to as “Orange Sunshine,” was meticulously crafted by Nick Sand and Tim Scully and became widely accessible in California. For a significant period, the hippie community believed this “Orange Sunshine” to be ALD-52. However, in 2005, Nick Sand disclosed that “Orange Sunshine” was, in fact, an exceptionally well-manufactured LSD batch, meticulously dosed at 300 micrograms per unit. This revelation was further substantiated by Tim Scully during a Reddit Ask Me Anything (AMA) session in 2017. Scully clarified that the assertion that “Orange Sunshine” was not technically LSD stemmed from an “ill-conceived, last-ditch defense strategy that ultimately proved unsuccessful” during his trial related to LSD production.


ALD-52, scientifically known as 1-Acetyl-N, N-diethyl lysergamide, belongs to the lysergamide chemical class and is a semisynthetic molecule. This compound is a derivative of lysergic acid and exhibits a distinctive structural arrangement featuring four interconnected rings. Specifically, it comprises a bicyclic hexahydroindole fused with a bicyclic quinoline group. ALD-52 incorporates elements reminiscent of tryptamine and phenethylamine structures within this fundamental framework. Additionally, ALD-52 possesses an N, N-diethyl carboxamide functional group bonded to position R8 within its chemical composition, along with an extra methyl substitution at carbon 6.
It’s worth noting that ALD-52 shares a structural similarity with 1P-LSD, which includes a propionyl group attached to CH3CO- instead of the acetyl group present at the same site. The exact implications of these structural disparities on the activities of the two compounds remain uncertain and necessitate further investigation.


ALD-52, acting primarily through its metabolite LSD, functions as a partial agonist affecting various serotonin receptor subtypes, including but not limited to the 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT6 receptors. Furthermore, it is anticipated to act as an agonist at dopamine receptors, specifically the D2 receptors. The psychedelic experiences associated with ALD-52 are attributed to its effectiveness at engaging with the 5-HT2A, 5-HT2C, and 5-HT1A receptor subtypes.
Notably, ALD-52, alongside 1P-LSD and 1B-LSD, serves as a prodrug for LSD, although it remains unclear whether it possesses distinct psychoactive effects as a parent compound. Research indicates that ALD-52 undergoes metabolic transformation, yielding two discernible metabolites: N-diethyl ALD-52 and N6-dimethyl ALD-52, commonly referred to as nor-ALD-52, in addition to its primary metabolite, LSD. This metabolic process is orchestrated by enzymes such as CYP3A4, responsible for N6-deallylation, and involves CYP2D6 in the hydroxylation process.

Subjective effects

ALD-52, similar to LSD in many anecdotal user reports, is often described as sharing virtually identical effects. In contrast to other psychedelics like psilocin, LSA, and ayahuasca, ALD-52 is notably more stimulating and characterized by a rapid-paced experience encompassing both physical and cognitive facets, a common trait among lysergamides.

Community anecdotes depict ALD-52 as slightly less potent and visually intense, offering a mellower and less anxiety-inducing mental state. However, some suggest that this might come at the cost of reduced depth, rendering it a more recreational variant of LSD. Speculation arises regarding its somewhat extended, less abrupt onset, allowing users to acclimate gradually to the shift in mental state. As dosages increase, ALD-52 is said to converge with the effects of a high-dose LSD experience.

It’s crucial to emphasize that the effects outlined below draw upon the Subjective Effect Index (SEI), which relies on anecdotal user accounts and personal analyses by contributors to PsychonautWiki. These experiences may not manifest consistently or predictably. Furthermore, higher doses escalate the risk of adverse effects, including addiction, severe injury, or even fatality ☠.


  • Stimulation: ALD-52 generates stimulating effects akin to LSD, differentiating it from other sedating psychedelics like psilocybin.
  • Spontaneous physical sensations: Characterized by intense tingling sensations, this “body high” exhibits euphoria and can manifest unpredictably or persistently during the trip.
  • Physical euphoria: While not as reliably inducible as stimulants or entactogens, this effect may vary from euphoria to physical discomfort.
  • Tactile enhancement: Users consistently report heightened tactile sensations, often culminating in an acute awareness of nerve endings throughout the body.
  • Changes in felt bodily form: These sensations often include a sense of warmth, unity, or physical connection to objects, accompanied by feelings of comfort and peace.
  • Perception of bodily lightness
  • Nausea: Mild nausea may occur at moderate to high dosages but typically subsides promptly, either post-vomiting or as the peak sets.
  • Stamina enhancement: Although present, this effect is milder than traditional stimulants.
  • Bodily control enhancement
  • Appetite suppression
  • Increased blood pressure
  • Increased heart rate
  • Increased perspiration
  • Muscle contractions
  • Muscle spasms
  • Difficulty urinating
  • Excessive yawning: Less pronounced compared to psilocybin and related compounds.
  • Pupil dilation
  • Increased salivation
  • Seizure: While no ALD-52-induced seizures have been documented, it might pose a similar risk to LSD, potentially lowering the seizure threshold, especially in predisposed individuals or adverse conditions like dehydration, undernourishment, overheating, or fatigue.


  • Enhancements:
    • Color enhancement: ALD-52 often intensifies colors, although with less variation.
    • Pattern recognition enhancement
    • Visual acuity enhancement
  • Distortions:
    • Drifting: This effect is highly detailed and resembles cartoon-like distortions, characterized by slow, smooth motion and fleeting appearances.
    • Colour shifting
    • Depth perception distortions
    • Perspective distortions
    • Symmetrical texture repetition
    • Tracers
  • Geometry: ALD-52’s visual geometry resembles 2C-B or 2C-I, featuring intricate, algorithmic, unstructured, brightly lit, multicolored, and sharp elements. It exhibits large, fast-moving, angular patterns with consistent intensity. Higher doses can lead to level 8B geometry under specific conditions.
  • Hallucinatory states: ALD-52 can induce a range of hallucinatory experiences, but they tend to be less consistent and vivid than those induced by other psychedelics like DMT or psilocybin mushrooms. These include transformations, internal hallucinations, and external hallucinations.


  • Analysis enhancement: ALD-52 consistently enhances analysis and introspection.
  • Anxiety & Paranoia: These effects are less common at low to moderate doses and less likely to occur with proper attention to setting and setting. Combining ALD-52 with cannabis may increase the risk of anxiety, particularly during the come-up phase.
  • Conceptual thinking
  • Creativity enhancement
  • Cognitive euphoria: Less consistent and pronounced than substances like psilocybin and MDMA.
  • Delusion
  • Déjà vu
  • Ego replacement
  • Emotion enhancement
  • Focus enhancement: Typically experienced at low or threshold dosages, with a less forced quality than stimulants.
  • Immersion enhancement
  • Increased libido
  • Increased music appreciation
  • Laughter fits: Prominent during the come-up phase, often leading to uncontrollable bouts of giggles when in the company of others under the influence.
  • Memory suppression
  • Ego death
  • Multiple thought streams
  • Novelty enhancement
  • Personal bias suppression
  • Personal meaning enhancement
  • Personality regression
  • Simultaneous emotions
  • Suggestibility enhancement
  • Thought acceleration
  • Thought disorganization
  • Thought loops
  • Time distortion
  • Wakefulness


  • Enhancements
  • Distortions
  • Hallucinations


  • Synaesthesia: A rare and non-reproducible effect, more likely to occur with higher dosages and among individuals predisposed to synaesthetic states.


  • Spirituality enhancement
  • Existential self-realization
  • Unity and interconnectedness


ALD-52 interacts with various substances in unique ways, with notable interactions including alcohol, benzodiazepines, cannabis, dissociatives, and MDMA, although the outcomes are often unpredictable. Users should exercise caution and begin with lower doses when combining substances, as interactions can potentiate effects or lead to unexpected reactions.


The toxicity and potential long-term health effects of recreational ALD-52 usage remain unexplored within scientific research due to its status as a research chemical and its limited history of human consumption.

Anecdotal evidence from individuals within the community who have experimented with ALD-52 at low to moderate doses used sparingly suggests minimal adverse health effects associated with the standalone use of the substance. Nevertheless, it is essential to stress that nothing can be unequivocally guaranteed without a comprehensive scientific investigation. Conducting independent research to ascertain the safety of combining two or more substances before consumption is crucial.

As observed with other psychedelic substances, there is a scarcity of reported physical side effects resulting from acute exposure to ALD-52. While no formal studies have been conducted, it is reasonable to assume, much like LSD itself, that ALD-52 exhibits a non-addictive nature and possesses an exceptionally low toxicity relative to dosage. Similarly, there are likely few to no detrimental physical, cognitive, psychiatric, or toxic consequences associated with acute ALD-52 exposure.

However, it’s worth noting that, akin to LSD and psychedelics in general, ALD-52 could potentially trigger individuals with underlying psychiatric conditions. Caution is advised, especially if there is knowledge of a family member having bipolar disorder or schizoaffective disorder, as individuals with personal or familial histories of mental illness are generally discouraged from using this substance, particularly outside a supervised medical context.

It is highly recommended that harm reduction practices be implemented when using ALD-52.

Tolerance and Addiction Potential:

Though no formal studies have been conducted, it is reasonable to assume, like LSD, that ALD-52 is not habit-forming and may even lead to a reduced desire for use with continued consumption.

Tolerance to ALD-52’s effects builds almost immediately following ingestion. Subsequently, it takes approximately 5-7 days for tolerance to halve and 14 days to return to baseline levels (without further consumption). Significantly, ALD-52 induces cross-tolerance with all psychedelics, meaning that its use diminishes the effects of other psychedelics.


The LD50 (lethal dose for 50% of subjects) of ALD-52 remains unknown. Adverse psychological reactions are relatively common, especially at higher doses. These reactions may encompass anxiety, delusions, panic attacks, and, more rarely, seizures. Medical attention typically becomes necessary only in severe psychotic episodes or if the consumed substance is suspected to be adulterated with other dangerous compounds like 25i-NBOMe or DOB. Administering benzodiazepines or antipsychotics may help alleviate adverse cognitive effects.

Dangerous Interactions:

It is crucial to exercise caution when combining substances, as many psychoactive compounds that are individually safe can become perilous when used together. Some known dangerous interactions include:

  • Lithium: Combining lithium, commonly prescribed for bipolar disorder, with psychedelics significantly heightens the risk of psychosis and seizures. This combination is strongly discouraged.
  • Cannabis: Cannabis may unpredictably intensify and synergize with ALD-52, potentially leading to adverse psychological reactions such as anxiety, paranoia, panic attacks, and psychosis. Users are advised to start with a fraction of their typical cannabis dose and take extended breaks between hits to avoid accidental overdose.
  • Stimulants: Substances like amphetamine, cocaine, or methylphenidate, which affect various brain regions and alter dopaminergic function, can increase the risk of anxiety, paranoia, panic attacks, and thought loops when combined with ALD-52. This interaction may also elevate the risk of mania and psychosis.
  • Tramadol: Tramadol is known to lower the seizure threshold, and psychedelics might trigger seizures in susceptible individuals. Therefore, caution is warranted when considering this combination.

Legal status

ALD-52 currently occupies a legal gray area in many parts of the world, meaning it is not explicitly classified as illegal in most countries. However, individuals may still face legal consequences related to their possession, primarily under specific circumstances, such as analog laws or when there is intent to sell or consume it.

Here is a breakdown of ALD-52’s legal status in various countries:

  • Austria: ALD-52 is not technically illegal in Austria, but it may be considered an analog of LSD and potentially fall under the Neue-Psychoaktive-Substanzen-Gesetz Österreich (NPSG).
  • Denmark: ALD-52 is not listed as an illegal substance in Denmark, and its chemical class, ‘lysergamide,’ is not prohibited under the Analogue Act. However, some LSD analogs are prohibited.
  • Germany: As of July 18, 2019, ALD-52 is controlled under Germany’s New Psychoactive Substances Act (NpSG). Production, import with the intent to market, administration to others, and trading are punishable. Possession is illegal but not penalized.
  • Latvia: ALD-52 is illegal in Latvia, even though it is not officially scheduled. It is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
  • Poland: ALD-52 is classified as a New Psychoactive Substance (NPS) in Poland, making it illegal to possess or distribute.
  • Singapore: ALD-52 is classified as a Class A controlled substance in Singapore.
  • Switzerland: ALD-52 is a controlled substance named explicitly under Verzeichnis E in Switzerland.
  • United Kingdom: As of January 7, 2015, ALD-52 is explicitly listed in the U.K. Misuse of Drugs Act as a Class A controlled substance.
  • United States: ALD-52 remains unscheduled in the United States. However, it may be considered an analog of LSD, a Schedule I controlled substance under the Controlled Substances Act. Consequently, the sale for human consumption or illicit non-medical or scientific research use could result in criminal prosecution under the Federal Analogue Act.


1. What is ALD-52? 

ALD-52, also known as 1-Acetyl-N, N-diethyl lysergamide, is a semisynthetic compound belonging to the lysergamide class. It is structurally related to LSD and is known for its psychedelic effects when consumed.

2. How does ALD-52 compare to LSD? 

ALD-52 is often reported to produce effects that are very similar to LSD. Many users describe the experiences as virtually identical. However, some anecdotal reports suggest that ALD-52 may have a slightly milder and less anxiety-inducing headspace than LSD.

3. Is ALD-52 legal? 

The legal status of ALD-52 varies by country. It is explicitly illegal in some places, while in others, it falls into a legal gray area. Researching and understanding the specific laws in your region is crucial before obtaining or using ALD-52.

4. What are the expected effects of ALD-52? 

The effects of ALD-52 can include visual distortions, changes in perception, enhanced tactile sensations, and altered thought processes. It is also known for producing hallucinatory states and can result in positive and negative experiences.

5. Is ALD-52 safe to use? 

The safety of ALD-52 use is not definitively established, as there is limited scientific research on its long-term effects. Like LSD, ALD-52 is generally not considered physically addictive or toxic, but it can lead to unpredictable psychological reactions, especially in individuals with underlying psychiatric conditions. Safe use should involve careful preparation and consideration of set and setting.

6. What is the recommended dosage of ALD-52? 

Dosage can vary significantly from person to person. A typical starting dose ranges from 100 to 150 micrograms, but some users may prefer higher or lower doses based on their experience and desired effects. It’s crucial to start with a low dose if you are inexperienced with psychedelics.

7. How long does an ALD-52 trip last? 

The effects of ALD-52 can last anywhere from 6 to 12 hours, depending on the dosage and individual sensitivity. The most intense phase of the trip typically occurs within the first 4 to 6 hours, followed by a gradual return to baseline.

8. Can ALD-52 be detected in drug tests? 

Standard drug tests do not typically screen for ALD-52, but it might trigger a false positive for LSD. However, the likelihood of being tested for ALD-52 specifically is relatively low.

9. What precautions should I take when using ALD-52? 

When using ALD-52, it is essential to prioritize safety. Start with a low dose if you are inexperienced, have a trusted and sober trip sitter present, and carefully select a comfortable and familiar setting (set and setting). Avoid combining ALD-52 with other substances, especially alcohol and cannabis, as it can intensify the effects and lead to unpredictable reactions.

10. Can I use ALD-52 for therapeutic purposes? 

While some individuals claim to have therapeutic experiences with ALD-52, clinical research does not support its use for this purpose. Always consult with a qualified mental health professional for guidance on therapeutic interventions.


  1. Troxler, F., Hofmann, A. (1957). “Substitutionen am Ringsystem der Lysergsäure I. Substitutionen am Indol-Stickstoff. 43. Mitteilung über Mutterkornalkaloide”. Helvetica Chimica Acta. 40 (6): 1706–1720. doi:10.1002/hlca.19570400619.
  2. Shulgin, Alexander; Shulgin, Ann (1997). “#26. LSD-25”. TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  3. Lüscher, Christian; Ungless, Mark A. (2006). “The Mechanistic Classification of Addictive Drugs”. PLOS Medicine. 3 (11). doi:10.1371/journal.pmed.0030437.
  4. Nichols, David E. (2016). Barker, Eric L., ed. “Psychedelics”. Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478.
  5. Strassmann, Rick (1984). “Adverse reactions to psychedelic drugs. A review of the literature”. Journal of Nervous and Mental Disease. 172 (10): 577–595. doi:10.1097/00005053-198410000-00001.
  6. “Ask Erowid: ID 3189: Was Orange Sunshine ALD-52?”. Erowid. Retrieved January 1, 2020.
  7. Aghajanian, G. K., Bing, O. H. L. (September 1964). “Persistence of lysergic acid diethylamide in the plasma of human subjects.” Clinical Pharmacology & Therapeutics. 5 (5): 611–614. doi:10.1002/cpt196455611.
  8. Marona-Lewicka, D., Thisted, R. A., Nichols, D. E. (July 2005). “Distinct temporal phases in the behavioral pharmacology of L.S.D.: dopamine D2 receptor-mediated effects in the rat and implications for psychosis”. Psychopharmacology. 180 (3): 427–435. doi:10.1007/s00213-005-2183-9.
  9. Titeler, M., Lyon, R. A., Glennon, R. A. (February 1988). “Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for L.S.D. and phenylisopropylamine hallucinogens”. Psychopharmacology. 94 (2). doi:10.1007/BF00176847.
  10. Burris, K. D., Breeding, M., Sanders-Bush, E. (September 1991). “(+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist”. The Journal of Pharmacology and Experimental Therapeutics. 258 (3): 891–896.
  11. Krebs-Thomson, Ph.D., K. (May 1998). “Effects of Hallucinogens on Locomotor and Investigatory Activity and Patterns: Influence of 5-HT2A and 5-HT2C Receptors”. Neuropsychopharmacology. 18 (5): 339–351. doi:10.1016/S0893-133X(97)00164-4.
  12. Moreno, J. L., Holloway, T., Albizu, L., Sealfon, S. C., González-Maeso, J. (April 2011). “Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists”. Neuroscience Letters. 493 (3): 76–79. doi:10.1016/j.neulet.2011.01.046.
  13. Wagmann, L., Richter, L. H. J., Kehl, T., Wack, F., Bergstrand, M. P., Brandt, S. D., Stratford, A., Maurer, H. H., Meyer, M. R. (July 2019). “In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.” Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9.
  14. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). “Potentiation of (DL)-3,4-methylenedioxymethamphetamine (MDMA)-induced toxicity by the serotonin 2A receptor partial agonist d-lysergic acid diethylamide (L.S.D.), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939”. Neuroscience Research Communications. 35 (2): 83–95. doi:10.1002/nrc.20023.
  15. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). “Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists”. European Journal of Pharmacology. 264 (3): 325–330. doi:10.1016/0014-2999(94)90669-6.
  16. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). “Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons”. Neurotoxicology. 28 (4): 868–875. doi:10.1016/j.neuro.2007.04.005.
  17. Passie, T.; Halpern, J. H.; Stichtenoth, D. O.; Emrich, H. M.; Hintzen, A. “The Pharmacology of Lysergic Acid Diethylamide: A Review.” C.N.S. Neuroscience & Therapeutics. 14: 295–314. doi:10.1111/j.1755-5949.2008.00059.x.
  18. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). “Dose-independent occurrence of seizure with tramadol.” Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089.
  19. Bundesgesetzblatt für die Republik Österreich (PDF), 1997.
  20. Samlet liste over euforiserende stoffer opført på bilag 1 til bekendtgørelsen om euforiserende stoffer nr. 557 af 31. maj 2011 og stoffer reguleret herefter via ændringsbekendtgørelser (in Danish). Lægemiddelstyrelsen [Danish Medicines Agency]. June 13, 2018.
  21. Anlage NpSG (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection].
  22. Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019.
  23. § 4 NpSG (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection].
  24. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005.
  25. Rozporządzenie Ministra zdrowia z dnia 21 sierpnia 2019 r. zmieniające rozporządzenie w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (PDF) (in Polish).
  26. Misuse of Drugs Act: (CHAPTER 185). sso.agc.gov.sg. March 31, 2008.
  27. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (in German). Bundeskanzlei [Federal Chancellery of Switzerland].
  28. Advisory Council on the Misuse of Drugs (June 10, 2014). “Update of the generic definition for tryptamines” (PDF). Government Digital Service.
  29. U.S.C. Title 21 – FOOD AND DRUGS.

Leave a Comment

Your email address will not be published. Required fields are marked *